0ZPN.F · Zosano Pharma Corporation

-

Please sign in to comment on 0ZPN.F

1 Comment

Admin

3 years, 7 months ago

Zosano Pharma Corporation is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.

From a valuation standpoint, the stock is 71.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 369.0.

Zosano Pharma Corporation's total revenue rose by inf% to $224K since the same quarter in the previous year.

Its net income has increased by 9.4% to $-8M since the same quarter in the previous year.

Finally, its free cash flow grew by 14.8% to $-7M since the same quarter in the previous year.

Based on the above factors, Zosano Pharma Corporation gets an overall score of 4/5.

Industry	Biotechnology
Sector	Healthcare
ISIN	None
CurrencyCode	EUR
Exchange	F

PE Ratio	None
Market Cap	19M
Target Price	None
Beta	2.97
Dividend Yield	0.0%

ABOUT

Zosano Pharma Corporation

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

0ZPN.F · Zosano Pharma Corporation

-

Zosano Pharma Corporation

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Zosano Pharma Corporation using a moving average strategy